Literature DB >> 18523970

New insights on the role of CXCR4 in cancer metastasis.

A Zlotnik1.   

Abstract

The evolutionarily conserved chemokine superfamily encodes small peptide molecules that bind G-protein-coupled receptors. In humans, this superfamily includes at least 46 ligands and 18 receptors. In general, chemokines and their receptors form a chemotactic network that regulates the migration of cells to specific micro-anatomical destinations within an organism in an organized and non-random manner. Recent studies place chemokine-chemokine receptor pairs at the centre of not only physiological cell migration, but also pathological processes such as metastasis. This mini review considers some recent data on how chemokines regulate tumour cells during metastasis. These observations suggest novel ways for pharmacological intervention. Copyright (c) 2008 Pathological Society of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18523970     DOI: 10.1002/path.2350

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  65 in total

Review 1.  Role of Forkhead Box Class O proteins in cancer progression and metastasis.

Authors:  Chang Geun Kim; Hyemin Lee; Nehal Gupta; Sharavan Ramachandran; Itishree Kaushik; Sangeeta Srivastava; Sung-Hoon Kim; Sanjay K Srivastava
Journal:  Semin Cancer Biol       Date:  2017-08-01       Impact factor: 15.707

2.  Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists.

Authors:  Beili Wu; Ellen Y T Chien; Clifford D Mol; Gustavo Fenalti; Wei Liu; Vsevolod Katritch; Ruben Abagyan; Alexei Brooun; Peter Wells; F Christopher Bi; Damon J Hamel; Peter Kuhn; Tracy M Handel; Vadim Cherezov; Raymond C Stevens
Journal:  Science       Date:  2010-10-07       Impact factor: 47.728

3.  A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells.

Authors:  Hiroshi Yagi; Wenfu Tan; Patricia Dillenburg-Pilla; Sylvain Armando; Panomwat Amornphimoltham; May Simaan; Roberto Weigert; Alfredo A Molinolo; Michel Bouvier; J Silvio Gutkind
Journal:  Sci Signal       Date:  2011-09-20       Impact factor: 8.192

4.  Discovery of novel N-aryl piperazine CXCR4 antagonists.

Authors:  Huanyu Zhao; Anthony R Prosser; Dennis C Liotta; Lawrence J Wilson
Journal:  Bioorg Med Chem Lett       Date:  2015-04-17       Impact factor: 2.823

5.  High-level CXCR4 expression correlates with brain-specific metastasis of non-small cell lung cancer.

Authors:  Gang Chen; Zhou Wang; Xiang-yan Liu; Fan-ying Liu
Journal:  World J Surg       Date:  2011-01       Impact factor: 3.352

6.  Adenosine arrests breast cancer cell motility by A3 receptor stimulation.

Authors:  Carola Ledderose; Marco M Hefti; Yu Chen; Yi Bao; Thomas Seier; Linglin Li; Tobias Woehrle; Jingping Zhang; Wolfgang G Junger
Journal:  Purinergic Signal       Date:  2016-08-30       Impact factor: 3.765

Review 7.  Proteolytic regulatory mechanism of chemerin bioactivity.

Authors:  Xiao-Yan Du; Lawrence L K Leung
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2009-12       Impact factor: 3.848

8.  Discovery of tetrahydroisoquinoline-based CXCR4 antagonists.

Authors:  Valarie M Truax; Huanyu Zhao; Brooke M Katzman; Anthony R Prosser; Ana A Alcaraz; Manohar T Saindane; Randy B Howard; Deborah Culver; Richard F Arrendale; Prahbakar R Gruddanti; Taylor J Evers; Michael G Natchus; James P Snyder; Dennis C Liotta; Lawrence J Wilson
Journal:  ACS Med Chem Lett       Date:  2013-09-05       Impact factor: 4.345

9.  SDF1-3' a gene polymorphism is associated with laryngeal cancer.

Authors:  Lukasz Kruszyna; Margarita Lianeri; Małgorzata Rydzanicz; Krzysztof Szyfter; Paweł P Jagodziński
Journal:  Pathol Oncol Res       Date:  2009-10-16       Impact factor: 3.201

10.  64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4.

Authors:  Orit Jacobson; Ido D Weiss; Lawrence Szajek; Joshua M Farber; Dale O Kiesewetter
Journal:  Bioorg Med Chem       Date:  2009-01-15       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.